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A B S T R A C T
Purpose: The present study was conducted with the aim of evaluating the effects of reducing the number
of antiepileptic drugs (AEDs) administered to patients with drug-refractory epilepsy (DRE) during their
admission and document any change in seizure frequency in subsequent follow up.
Methods: A total of 962 patients with DRE who were admitted to the neurology wards waiting for
connection to video EEG were recruited for this prospective study. After their admission to the neurology
ward, modiﬁcations in the number and dosage of AEDs were done with a target of a maximum of three
AEDs in every patient. Drug tapering was done using a standardized protocol. The primary outcome was
the change in seizure frequency in the follow-up period of 6 months. Secondary outcome measures were
the adverse event proﬁle (AEP) and the quality of life (QOL).
Results: Of the 1134 patients screened, 962 patients gave consent to participate in the study. The mean
number of AEDs received by each patient was 4.24. After the tapering following a standardized protocol
each patient received a mean of 2.65 AEDs per patient. In 82.70% patients with DRE, there was either a
reduction or no change in seizure frequency in the subsequent 6 months follow up. There was a
signiﬁcant reduction in the AEP score after the reduction in the number of AEDs (P = 0. 001).
Conclusion: Our study proves that optimization of reduction of the number of AED’s in patients with DRE
leads to reduction or no change in seizure frequency with a signiﬁcant decrease in adverse effects.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Despite recent advances in neuropharmacology, around
20–30% of persons with epilepsy (PWE) have DRE. Most of them
are on multiple AEDs with the hope of achieving good seizure
control [1]. Although there is evidence that there is a decreased
chance of seizure control after failure of an adequate trial of ﬁrst-
line AEDs, polytherapy is rampant in clinical practice.
Polytherapy increases the side effects of medications through
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monitoring more difﬁcult. Moreover, some AEDs are known to
aggravate pre-existing seizures and trigger new seizure types [15].
There is evidence from previous studies that reduction of one or
more AED is possible without an increase in seizure frequency in
patients with DRE [2,3,14].
Uncontrolled epilepsy leads to an increase risk of death,
cognitive and behavioral dysfunction and socioeconomic disad-
vantage. All attempts should be made to make the patient seizure
free, but not at the cost of a poor QOL. The present study aims to
evaluate the effects of reducing the number of AEDs administered
to patients with DRE during their stay in the neurology ward and
the likelihood of decrease and non-increase in seizure frequency in
subsequent 6 month follow up.
2. Methods
A total of 1134 patients of DRE who were being evaluated in the
EMU from 2003 to 2012 were identiﬁed and were screened for the
study. Out of them 962 were recruited for this prospective studyserved.
Table 1
Etiology and seizure types.
Etiology Number
Etiology of seizures
Mesial temporal sclerosis 226 (24.0%)
Perinatal hypoxia 225 (23.9%)
Cortical dysplasia 198 (21.0%)
DNETs 56 (5.9%)
Gliosis secondary to infarction 45 (4.7%)
Post traumatic gliosis 43 (4.5%)
Gangliogliomas 41 (4.3%)
Post Infectious 32 (3.3%)
No substrate 96 (10.2%)
Types of seizures
Focal dyscognitive seizures 607 (63.1%)
Focal motor seizures 34 (0.3%)
Focal sensory 6 (0.6%)
Focal progressing to bilateral convulsive- 28 (2.9%)
Drop attacks 192 (2.0%)
Myoclonus 23 (2.3%)
Multiple seizure types 31 (3.2%)
Reﬂex epilepsy (sound, touch, eating) 21 (2.1%)
Generalized tonic 16 (1.7%)
Clonic 1 (0.1%)
PNES plus focal seizures 3 (0.3%)
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institute ethical committee. Informed consent was sought from the
patient or and caregiver after explaining the details of the study in
the language the patient could understand, by an epilepsy fellow.
Patients and or their caregivers were also explained the possible
risk of increase in seizure frequency during the study. Out of the
172 patients who declined to the study, 124 did so due to their
inability to come for a timely follow up (As they were residing in
remote rural areas) and 48 declined after they were explained the
possible risk of increase in seizure frequency during the study. DRE
was deﬁned as failure of adequate trials of two tolerated and
appropriately selected and used AED schedules (in combination) to
achieve sustained seizure freedom.
Inclusion criteria consisted of patients with DRE being treated
with at least three or more AEDs with seizure frequency of at least
1 per month. Frequency of seizures was determined as an average
of the previous 6 months. PWE with catastrophic epilepsies like
Rasmussen encephalitis, malignant brain tumors and severe
central nervous system infections like fungal infections, prion
diseases, progressive multifocal leukoencephalopathy were ex-
cluded.
Patients were enrolled into the study after admission to
neurology wards while they were waiting for connection to VEEG
either for characterization of seizure type or as a work up for
epilepsy surgery. Clinical, demographic, diagnostic evaluation and
treatment-related details were recorded in all patients after an
interview in a structured proforma. Details regarding the age of
onset of seizures, the semiology of seizures, frequency of seizures,
any history of status epilepticus was recorded. Treatment details
included the number of AEDs prior to the monitoring, their
combinations, dose adequacy, AED levels and side-effect proﬁle.
After their admission AED’s were tapered gradually. The tapering
of AEDs was done after admission in neurology wards prior to
transfer to the EMU. A slow tapering protocol was done after
reviewing the history and response to each AED- in situations
where a deﬁnite history of response to a particular AED was seen,
then that AED was not tapered. Those AEDs which were enzyme
inducing and had produced no response were tapered ﬁrst. In
situations where it was not clear if there was any AED which has
produced a response an enzyme inducing AED/those AEDs which
were producing an adverse effect were tapered ﬁrst. Dosage of
tapering was only 25% of the dosage of AED per day. Phenobarbi-
tone was reduced at a slower rate of 10% of the dosage.
Benzodiazepines were not tapered so as to not provoke withdrawal
seizures. After the patients underwent VEEG recording and an
adequate number of seizures were recorded, the AED’s were
restarted. Modiﬁcations in the number and dosage of AEDs were
done and the target was to keep the patient on a maximum of three
AEDs. These would be the ones to which the patient had good
response as per routinely maintained seizure charts and diaries
and caregivers information. The choice of drugs was based on the
treating epileptologists (MT) review, to be either that which was
producing maximum side effects or was ineffective. Serum drug
levels were done in all patients and drug dosage titration was done
according to the drug levels. The primary outcome was the change
in seizure frequency in the follow-up period of 6 months after
reduction of the number of AEDs. Seizure frequency was
determined from a seizure diary completed by the patient or
caregiver, which was reviewed at routine monthly clinic visits.
Secondary outcome measures were the AEP and the QOL. Adverse
effects (AEs) were identiﬁed by the AEP questionnaire comprising
of 21 questions. The AEP score has been widely used in epilepsy
research [4–8]. The frequency of occurrence of each AE in the
previous 4 weeks was rated on a 4-point digital scale (4 = frequent,
3 = sometimes, 2 = rarely and 1 = no occurrence). The total score, as
a sum of the individual AED rating, indicates the total burden ofAED’s adverse effect. The patient AEP score was calculated at
baseline and again after 6 months of the reduction of an AED.
We used Hindi translation of QOLIE-10, which is a self-
administered questionnaire. It comprises of 10 questions about
health and daily activities, one question about how much distress
the person feels about problems and worries related to epilepsy
and a review of what is most bothersome. The responses of the
questionnaire were recorded. We also determined Cronbach’s
alpha, a marker of reliability to indicate how closely related a set of
items are as a group. A relative coefﬁcient of 0.7 or higher is
considered acceptable in most situations. We found a reliability
coefﬁcient of 0.94. Further, all domains of QOL correlated well with
each other indicating that these domains were interlinked. The
follow-up assessment was done by a neurologist (VA) and
pharmacologist (RJ) blinded to the patient treatment protocol.
The seizure frequency and AEP score at 6-month follow up was
compared to the baseline frequency.
3. Results
3.1. Subject characteristics
Of the 962 patients, 595 (61.8%) were males and 367 (39%) were
females. The mean age at the time of presentation was
19.97  11.37 years. Most of the patients (884, 93.84%) were under
40 years and 270 patients (28.66%) were under 10 years of age. The
mean duration of epilepsy was 7.21 years (range: 1–28 years) and in
most the duration of epilepsy was under 10 years (762 patients,
80.89%). The mean age of onset of epilepsy was 12.76 years with a
range of 0.6–59 years. The etiology and seizure types are tabulated in
Table 1.
3.2. Seizure frequency after reducing the number of AED
The mean number of AEDs received by each patient was 4.24
with a range of 3–6 AEDs. Most of the patients (58.38%) were
receiving 4 AEDs while only 15 patients (1.59%) were on 6 AEDs.
The average duration of stay of patients in the EMU was 5.4  2.1
days. The total duration of stay of patients in hospital was 11.2  3.2
days. After the tapering each patient received 2–3 AEDs with a mean
of 2.65 AED per patient. The number of patients exposed to an
individual AED has been depicted in Table 2.
Table 2
Exposure of individual AED to number of patients.










Percentage of patients with either no change or decrease in seizure frequency in
follow up.
Follow up period Percentage of patients with no change or
decrease in seizure frequency in follow up
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Fig. 2. Percentage of patients in various categories of AEP scores at initial
assessment and after 6 months of follow up of tapering of AED’s.
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follow up and 942 could be followed up after 6 months. The
percentage of patients with either no change or decrease in seizure
frequency at 6 months follow up was 82.70%. Table 3 shows the
percentage of patients with either no change or a decrease in
seizure frequency at different follow up periods. Cox regression
analysis was done to calculate predictors of decrease in seizure
frequency on reduction of number of AED’s. The signiﬁcant
negative predictors of decrease in seizure frequency after tapering
the number of AED’s included a history of status epilepticus,
younger age of onset of epilepsy, presence of mental retardation
and ﬁndings of perinatal hypoxia on MRI.
Two patients had status epilepticus in the ﬁrst month after
tapering of drugs and one had status in the second month. In
82.70% of our patients there was a reduction or no change in
seizure frequency in the subsequent 6 months follow up. In 56%
patients, there was a decrease in seizure frequency after reduction
of number of AEDs. The mean reduction of seizures per patient was
0.50 which was highly signiﬁcant (P value <0.001, 95% CI 0.39–
0.61). Out of the 942 patients, 17 had an increase in seizure
frequency with a mean seizure frequency of 3.5 prior to the change
in AED number to 4.5 after the tapering of AED’s. History of prior
episodes of status epilepticus was found to be a signiﬁcant
negative predictor for the reduction of seizure frequency after
decrease in the number of AEDs. Out of 17 patients who had
worsening of seizures after reduction of AEDs and the history of
status epilepticus was present in 15 patients (88.23%).
None of the patients had epilepsy surgery during the study
period. This is because of an average waiting period of at least 12
months for surgery in our hospital after the evaluation in the EMU.
Of the 942 patients 718 subsequently underwent epilepsy surgery
after discussion in our weekly presurgical case conference.
3.3. Adverse effect proﬁles
The adverse effects encountered before tapering the AEDs and
after 6 months of tapering of number of AEDs have been depicted
in Fig. 1. Drowsiness, ataxia and double vision were found to be
signiﬁcantly decreased at 6 months following reduction of the
AEDs (50.73%, 49.57% and 65%, respectively). The mean AEP score
at baseline was 64.2  8.3. The AEP score after reduction in the
number of AED’s at 6 months follow up decreased to 40.4  7.8. There
was a signiﬁcant reduction in the AEP score before and after reduction
of number of AEDs (P = 0. 001). We categorized AEP scores into 5subgroups 21–30, 31–40, 41–50,51–60 and >60. We calculated the
percentage of patients having AEP scores in different categories at the
initial assessment and after 6 months follow up of tapering of AED’s
(Fig. 2).
3.4. Quality of life
The mean total QOLIE-10 score at baseline was 56  19 and at 6
months after a reduction in the number of AEDs was 62  14 and this
was not statistically signiﬁcant. The ratings of QOL on all parameters
were almost comparable for patients on two AEDs as well as on three
AEDs.
4. Discussion
We enrolled 962 consecutive patients of DRE, admitted for
evaluation in the EMU who were on at least three or more AEDs.
The number of AEDs in these patients was reduced to a maximum
of 3 during their stay in the neurology wards. They were
subsequently followed up for next 6 months. In 82.70% of our
patients there was either a reduction or no change in seizure
frequency observed after decreasing the number of AEDs. There
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reduction of the number of AEDs. The mean reduction of seizure
per patient was 0.50 which was statistically signiﬁcant (P value
<0.001, 95% CI 0.39–0.61). Adverse effects which included
drowsiness, ataxia and double vision were found to be signiﬁcantly
decreased 6 months after reduction of the AEDs (50.73%, 49.57%
and 65%, respectively). There was a signiﬁcant reduction in the AEP
score before and after reduction of number of AEDs (P = 0. 001).
Matsuura prospectively evaluated the effect of polytherapy
reduction on patient satisfaction and subjective seizure severity in
patients with chronic epilepsy [9]. AEDs were withdrawn using a
1-year reduction schedule. In the cohort of 80 patients with
chronic epilepsy, there was reduction of seizure frequency in 9
patients. Seizure frequency remained stable in 69 out of 80
patients even after reduction of AEDs. They also found that no
patient had an increase in seizure frequency after withdrawal of
sedative groups of the AEDs. QOL was assessed by the authors on
the side effect and life satisfaction (SEALS), which is a self-reported
questionnaire developed by Brown and Tomlinson for use in
community surveys to evaluate side effects of AED [10]. After
reduction of number of AEDs, total SEALS score improved and also
the temper sub score improved. The total SEALS score and temper
sub score were not affected by the type of epilepsy or change in
seizure frequency. The authors concluded that the improvement in
QOL score used was probably due to the reduction in the adverse
effects of the AEDs. In contrast, our study did not ﬁnd a signiﬁcant
improvement in the QOLIE-10 scores after a reduction in the
number of AEDs. This could be probably because of the short
duration of follow-up period. The other reason could be that as
most of our patients had a very low educational background and
the questionnaire was self-administered. This could have led to
them not understanding the scoring system. Assistance in the form
of an epilepsy nurse explaining the scoring system may have
brought out different results. The scale used to measure QOL was
also different compared to the one used by Matsuura.
Albright and Bruni conducted a study and attempted to reduce
the number of AEDs in 90 patients with epilepsy (Albright [13] and
Bruni 1982). In 72 patients (80%), the mean number of drugs
administered were reduced from 2.75 to 1.49. 39 (54%) of these
patients were converted to monotherapy. Patients were followed
up for a minimum of 16 months after reduction of polypharmacy
and were found to have either no change or an improvement in
seizure control. The authors also noted a signiﬁcant decrease in
AEP. The variable predicting failure in reducing polypharmacy was
the presence of multiple concurrent seizure types. In the present
study, patients were on a larger number of AEDs to begin with, but
even then a similar trend of no change or reduction in seizure
frequency was noted after a 6-month follow up.
In a retrospective chart review by Richardson et al. [16], 35
patients of DRE who had been shifted from polytherapy to
monotherapy were identiﬁed and followed for at least 12 months.
Out of 35 patients, none had worsening of their seizure frequency.
A signiﬁcant proportion of patients (40%) became seizure-free. Out
of 35 patients, 28 (80%) had a 50% or greater reduction in seizure
frequency. None of the 35 patients had worsening of seizure
frequency. QOL on monotherapy was better as compared with
polypharmacy in a number of domains: memory loss, concern over
medication long-term effects, difﬁculty in taking the medications,
trouble with leisure time activities, and overall state of health [16].
In contrast to Richardson et al., our study design was prospective in
nature and the assessor of ﬁnal outcome was blinded to the
treatment protocol thus decreasing the chances of bias. In our
study, 56% patients had a decrease in seizure frequency after
reduction of number of AEDs The plausible explanation could be
that our cohort had a more refractory variety of DRE (mean seizure
frequency was 4.8/month).In our cohort of DRE patients the drugs were reduced after the
patient was admitted to the wards for the evaluation and work up
for epilepsy surgery. The patients were connected to VEEG and
seizure type and EEG correlates were studied. Drug tapering was
done in this setting. Seizure type and epilepsy syndrome could be
better characterized by the treating neurologist thus AEDs tailored
for the speciﬁc seizure type were continued and the AEDs which
were having minimal or no effect were tapered off.
The other reason could be due to the reduction in number of
AEDs, the pharmacokinetic and pharmacodynamic drug interac-
tions were minimized. Thus, the drug levels achieved were better
and probably resulted in a better seizure control. A decrease in the
number of drugs also leads to better compliance; a reduced cost
and also may result in a decrease in seizure frequency.
It is well established that seizure frequency can show
ﬂuctuations in a patient of DRE as part of the natural course of
the DRE. With an average duration of epilepsy for 7.21 years, it is
unlikely that a spontaneous remission in seizure frequency could
explain the magnitude of improvement seen in our cohort of DRE
patients.
There is growing evidence indicating that AEDs may worsen
pre-existing seizures by increasing their frequency or inducing a
new type of seizure. Carbamazepine, oxcarbazepine, and phenyt-
oin can aggravate absence and myoclonic seizures; to a lesser
extent, atonic seizures; and, more rarely, tonic seizures. Absence
and myoclonic seizures are triggered by all of the GABAergic drugs.
Severe myoclonic epilepsy of infancy seems to be predictably
aggravated by lamotrigine. There are reports in the literature
reporting precipitation of status epilepticus due to AEDs [11]. By
decreasing the number of AEDs the risk of paradoxical increase in
the seizure frequency is relatively reduced.
The proportion of patients with an increase in seizure frequency
was approximately 18% in our study. This is similar to what
Schmidt reported in prospective studies of 36 patients with
intractable complex partial seizures where two-drug treatment
regimen was converted to a single-drug therapy [2]. In a long-term
population-based study of 144 patients followed up for 37.0 years
since their ﬁrst seizure before the age of 16 years, a worsening of
seizure frequency was seen in 14% of patients [12].
Our study is probably the largest study, which has seen the
effect of reducing the number of AEDs in DRE patients during their
stay in neurology ward and the impact on seizure frequency in the
subsequent months. The strength of our study is the large number
of patients and the prospective design of our study. It is the largest
published study looking into the effect of decreasing polyphar-
macy in patients of DRE in a prospective manner.
5. Conclusion
Our study proves that it is not worthwhile to give more than
three AEDs in patients with DRE. Seizures can be controlled better
and adverse reactions can be reduced with a less number of drugs.
However, sometimes just changing combinations and dose
adjustments could reduce the number of side effects and improve
seizure control.
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